Innovent Biologics, Inc., a biopharmaceutical company that develops, manufacturers, and commercializes top-class medicines, has recently announced the outcomes of high-dose cohorts in Phase 1 clinical study of mazdutide (IBI362), a glucagon receptor dual agonist, and a glucagon-like petide-1 (GLP-1), in adults in China with obesity or overweight at ENDO 2022.

As per credible sources, this placebo-controlled, randomized, double-blind, multiple-ascending-dose study examined the tolerability, safety, and PK/PD features of mazdutide in Chinese participants with obesity or overweight. Each cohort of participants established administration for 12 weeks, except those members in cohort 4 received administration for 16 weeks.

The study's principal investigator, Professor Linong Ji from Peking University People's Hospital, stated that the obese population of China had surpassed 100 million. Most patients cannot achieve weight loss owing to the lifestyle intervention, specifying the urgent requirement for a highly effective and safe weight loss treatment.

The country is pleased to see high-dose mazdutide demonstrating a similar safety profile while showcasing more effective weight loss and several benefits in metabolic parameters.

While commenting on the outcomes, Vice President of Clinical Development of Innovent, Dr. Lei Qian said that the high dose of mazdutide demonstrated satisfactory safety, admissibility, and robust efficacy for weight loss in Chinese patients with obesity or overweight.

Mazdutide is the only molecule to accomplish a 12-week weight loss by around 11.5% among single-agent anti-obesity molecules authorized or under development.

These results showcase the dominance of glucagon receptor dual agonists and GLP-1 around GLP-1 receptor mono-agonists in terms of losing weight.

Moreover, as per the recent reports, the study also authorized the multiple metabolic assistances offered by mazdutide to patients with obesity or overweight. The firm is also planning to continue developing the high-dose mazdutide in obesity and overweight and other potential indications apart from the different exciting results.

Source Credit - https://www.prnewswire.com/news-releases/innovent-releases-results-of-high-dose-cohorts-in-phase-1-clinical-study-of-mazdutide-ibi362-in-chinese-adults-with-overweight-or-obesity-at-endo-2022-301566184.html